Matches in Wikidata for { <http://www.wikidata.org/entity/Q74616021> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- Q74616021 description "artikull shkencor i botuar më 01 shkurt 1999" @default.
- Q74616021 description "artículu científicu espublizáu en febreru de 1999" @default.
- Q74616021 description "im Februar 1999 veröffentlichter wissenschaftlicher Artikel" @default.
- Q74616021 description "scientific article published on 01 February 1999" @default.
- Q74616021 description "wetenschappelijk artikel" @default.
- Q74616021 description "наукова стаття, опублікована в лютому 1999" @default.
- Q74616021 name "Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups" @default.
- Q74616021 name "Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups" @default.
- Q74616021 name "Zenapax" @default.
- Q74616021 type Item @default.
- Q74616021 label "Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups" @default.
- Q74616021 label "Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups" @default.
- Q74616021 label "Zenapax" @default.
- Q74616021 prefLabel "Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups" @default.
- Q74616021 prefLabel "Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups" @default.
- Q74616021 prefLabel "Zenapax" @default.
- Q74616021 P1433 Q74616021-83F6C195-9A11-437B-ACCD-65136B05ACB1 @default.
- Q74616021 P1476 Q74616021-58151AF3-480A-4111-8CE7-99D8EC56F4FA @default.
- Q74616021 P2093 Q74616021-4E31D4A3-E136-4E0A-84A0-0F5E560D7EBE @default.
- Q74616021 P2093 Q74616021-A754DAEB-A1EB-468D-BC21-E062C1AC6B24 @default.
- Q74616021 P2093 Q74616021-C0CD1A5B-3254-4A2B-A933-94B11AA6C7D2 @default.
- Q74616021 P2093 Q74616021-F533C8F7-24E9-44C0-87D7-4DF42C16B866 @default.
- Q74616021 P2860 Q74616021-3F0A670D-E12A-43B5-9C76-14FE01EFF2B0 @default.
- Q74616021 P2860 Q74616021-43A269EF-395F-4C69-90D9-1A58A79514A7 @default.
- Q74616021 P2860 Q74616021-4903561E-506E-41CE-947C-2DB990DA885E @default.
- Q74616021 P2860 Q74616021-546F2B22-54D0-4545-9789-E206E659BFF0 @default.
- Q74616021 P2860 Q74616021-56C3CCCA-B74A-4DB7-8273-7CDD131102CD @default.
- Q74616021 P2860 Q74616021-8EF4D9DD-F77C-46DF-843A-06E45CEF44E5 @default.
- Q74616021 P2860 Q74616021-92327013-69AF-4D07-ABE1-B5425710B03A @default.
- Q74616021 P2860 Q74616021-9B439401-89E9-4754-BCA8-109653BB8F5A @default.
- Q74616021 P2860 Q74616021-A1844A95-8037-4CA0-9BF0-05DE468364A4 @default.
- Q74616021 P2860 Q74616021-F3ADF231-6777-4F30-91CF-D94785B2D10C @default.
- Q74616021 P304 Q74616021-62B56B00-AA8D-4674-85FB-3CCB4E9B0056 @default.
- Q74616021 P31 Q74616021-D499C193-F195-4004-8541-C4F8DF2E0165 @default.
- Q74616021 P356 Q74616021-8B860EF0-BA98-4788-9437-6402E4D65DB2 @default.
- Q74616021 P407 Q74616021-86332524-D46A-45BE-BAC6-1E85260E2B1A @default.
- Q74616021 P433 Q74616021-0A560C0A-7B3D-4E92-8C3F-7F319D0003B4 @default.
- Q74616021 P478 Q74616021-93B6701D-D6F6-404C-B471-D982EE5C6AB2 @default.
- Q74616021 P577 Q74616021-5FD0F62F-AA1D-4E8B-949C-948B5069223E @default.
- Q74616021 P698 Q74616021-89D64515-78B2-4208-95EF-CCAAFAE550C8 @default.
- Q74616021 P356 S0041-1345(98)01529-2 @default.
- Q74616021 P698 10083102 @default.
- Q74616021 P1433 Q7834825 @default.
- Q74616021 P1476 "Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups" @default.
- Q74616021 P2093 "G Tufveson" @default.
- Q74616021 P2093 "G Tydén" @default.
- Q74616021 P2093 "H Ekberg" @default.
- Q74616021 P2093 "L Bäckman" @default.
- Q74616021 P2860 Q24600912 @default.
- Q74616021 P2860 Q35759097 @default.
- Q74616021 P2860 Q40891371 @default.
- Q74616021 P2860 Q42670216 @default.
- Q74616021 P2860 Q47887130 @default.
- Q74616021 P2860 Q67912244 @default.
- Q74616021 P2860 Q68455768 @default.
- Q74616021 P2860 Q71983561 @default.
- Q74616021 P2860 Q74038855 @default.
- Q74616021 P2860 Q77916212 @default.
- Q74616021 P304 "267-268" @default.
- Q74616021 P31 Q13442814 @default.
- Q74616021 P356 "10.1016/S0041-1345(98)01529-2" @default.
- Q74616021 P407 Q1860 @default.
- Q74616021 P433 "1-2" @default.
- Q74616021 P478 "31" @default.
- Q74616021 P577 "1999-02-01T00:00:00Z" @default.
- Q74616021 P698 "10083102" @default.